Clobetasol Suspension Eases Cataract Inflammation

Phase 3 trials show clobetasol propionate ophthalmic suspension rapidly reduced inflammation and pain after cataract surgery

1

Clobetasol propionate ophthalmic suspension 0.05% may effectively control inflammation and pain after cataract surgery.
2

In Phase 3 trials, clobetasol showed rapid reductions in postoperative inflammation and ocular pain compared to placebo.
3

Patients treated with clobetasol achieved better visual acuity recovery by day eight post-surgery than those receiving placebo.
4

The treatment demonstrated a safety profile comparable to placebo, with no significant intraocular pressure increases.
5

Clobetasol's nanoparticle formulation improves ocular penetration and ease of use, particularly for elderly patients.

1